INMB — INmune Bio, Inc.

Summary of INmune Bio Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Net Loss: $45.9 million for the year ended December 31, 2025, compared to $42.1 million in 2024.
• Research and Development Expenses: Decreased to $20.7 million from $33.2 million in 2024, primarily due to lower costs associated with the Alzheimer's trial.
• General and Administrative Expenses: Increased to $10.3 million from $9.5 million in 2024.
• Impairment: A full impairment of intangible assets was recorded at $16.5 million following the Phase II results of the Alzheimer's trial.
• Cash Position: Approximately $24.8 million in cash and cash equivalents as of December 31, 2025, expected to fund operations through Q1 2027.

2. Strategic Updates and Business Highlights

• CORDStrom Program: Advancements in the treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) were highlighted, with plans to submit a Marketing Authorization Application (MAA) in the U.K. by mid-summer 2026. The product shows promise in wound healing and quality of life improvements.
• XPro Program: The MINDFuL Phase II trial for Alzheimer's disease was completed, and the company is preparing for a Phase III trial, having aligned with the FDA on the development path.
• INKmune: The Phase II trial in metastatic castration-resistant prostate cancer was completed ahead of schedule and under budget, meeting its primary endpoint and two secondary endpoints.

3. Forward Guidance and Outlook

• 2026 Priorities: Focus on advancing CORDStrom towards regulatory approval, clarifying next steps for XPro, and building partnerships to support program development.
• Regulatory Submissions: Plans to submit the MAA to the EMA and the BLA to the FDA by the end of 2026, with potential approvals expected in 2027.

4. Bad News, Challenges, or Points of Concern

• Alzheimer's Trial Results: The MINDFuL trial did not meet its top-line primary endpoint, which raises concerns about the program's viability and future funding.
• Impairment of Intangible Assets: The significant impairment indicates challenges in the Alzheimer's program, which could affect investor confidence.
• Regulatory Challenges: The need to create new master seedstock for U.S. submissions due to FDA requirements may delay the approval process.

5. Notable Q&A Insights

• Differences in Regulatory Requirements: Mark Lowdell addressed the differences between MAA and FDA submissions, confirming that U.K. donor materials can be used for U.S. submissions with specific testing requirements.
• Partnership Discussions: David Moss indicated ongoing discussions with potential partners for the XPro program, emphasizing the attractive market potential and logical correlation between cognitive and functional measures in Alzheimer's treatment.
• Future Funding: The company is actively seeking partnerships and funding to support late-stage development, particularly for the XPro program, which is seen as a significant opportunity.

Overall, INmune Bio's 2025 earnings call highlighted a year of significant progress in clinical development despite facing challenges, particularly with the Alzheimer's program. The company is strategically positioned for 2026 with clear objectives and regulatory pathways, although investor concerns remain regarding the viability of certain programs.